
Please try another search
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
Lewis H. Bender | 65 | 2012 | Founder, President, CEO & Chairman of the Board |
Riccardo Lencioni | - | 2015 | Member of Scientific Advisory Board |
Emer Leahy | 58 | 2016 | Independent Director |
Mario Sznol | 66 | 2015 | Member of Scientific Advisory Board |
Jay A. Berzofsky | - | - | Member of Scientific Advisory Board |
Chris J. Viau | - | - | Member of Scientific Advisory Board |
Mark A. Goldberg | 64 | 2018 | Independent Director |
Thomas I. H. Dubin | 62 | 2024 | Independent Director |
Daniel J. Donovan | 60 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review